Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Doherty

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Human Psychopharmacology|April 4, 2017
Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depressionStephen J Kanes, Helen Colquhoun, James Doherty, et al.
The Journal of Trauma|July 12, 2007
Prospective randomized control trial of intermittent versus continuous gastric feeds for critically ill trauma patientsJana B A MacLeod, Jennifer Lefton, Doug Houghton, et al.
Integrative Zoology|March 12, 2011
Vertebrate pesticide risk assessment by indigenous communities in New ZealandShaun C Ogilvie, James M Ataria, James Waiwai, et al.
Emergency Medicine Journal : EMJ|September 27, 2023
Journal update monthly top fiveJoanna Sutton-Klein, William James Doherty, Anisa Jabeen Nasir Jafar, et al.
The Journal of Trauma and Acute Care Surgery|January 10, 2024
Trauma surgeons experience compassion fatigue: A major metropolitan area surveyLea Hoefer, Leah C Tatebe, Purvi Patel, et al.
Clinical and Translational Science|July 11, 2024
Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's diseaseAaron Koenig, Michael Lewis, Jeff Wald, et al.
Clinical Pharmacokinetics|July 25, 2019
SAGE-217, A Novel GABA<sub>A</sub> Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding StudiesEthan Hoffmann, George G Nomikos, Inder Kaul, et al.
Synapse (New York, N.Y.)|May 28, 2010
Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268John R Zysk, Dan Widzowski, Linda A Sygowski, et al.
Trauma Surgery & Acute Care Open|June 12, 2023
When public health crises collide: 5 years of pediatric firearm injury prevention opportunitiesLeah C Tatebe, Jennifer T Cone, Mark B Slidell, et al.
The American Journal of Psychiatry|May 3, 2023
Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 TrialAnita H Clayton, Robert Lasser, Sagar V Parikh, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Human Psychopharmacology|April 4, 2017
Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depressionStephen J Kanes, Helen Colquhoun, James Doherty, et al.
The Journal of Trauma|July 12, 2007
Prospective randomized control trial of intermittent versus continuous gastric feeds for critically ill trauma patientsJana B A MacLeod, Jennifer Lefton, Doug Houghton, et al.
Integrative Zoology|March 12, 2011
Vertebrate pesticide risk assessment by indigenous communities in New ZealandShaun C Ogilvie, James M Ataria, James Waiwai, et al.
Emergency Medicine Journal : EMJ|September 27, 2023
Journal update monthly top fiveJoanna Sutton-Klein, William James Doherty, Anisa Jabeen Nasir Jafar, et al.
The Journal of Trauma and Acute Care Surgery|January 10, 2024
Trauma surgeons experience compassion fatigue: A major metropolitan area surveyLea Hoefer, Leah C Tatebe, Purvi Patel, et al.
Clinical and Translational Science|July 11, 2024
Dalzanemdor (SAGE-718), a novel, investigational N-methyl-D-aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose-finding studies in healthy participants and an open-label study in participants with Huntington's diseaseAaron Koenig, Michael Lewis, Jeff Wald, et al.
Clinical Pharmacokinetics|July 25, 2019
SAGE-217, A Novel GABA<sub>A</sub> Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding StudiesEthan Hoffmann, George G Nomikos, Inder Kaul, et al.
Synapse (New York, N.Y.)|May 28, 2010
Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268John R Zysk, Dan Widzowski, Linda A Sygowski, et al.
Trauma Surgery & Acute Care Open|June 12, 2023
When public health crises collide: 5 years of pediatric firearm injury prevention opportunitiesLeah C Tatebe, Jennifer T Cone, Mark B Slidell, et al.
The American Journal of Psychiatry|May 3, 2023
Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 TrialAnita H Clayton, Robert Lasser, Sagar V Parikh, et al.
Pageof 5